MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today that the Board of Patent Appeals and Interferences of the U.S. Patent Office (“BPAI”) has reversed an earlier decision from the Patent Office reexamination division that had upheld the claims of U.S. Patent Number 7,029,913. The patent, which is assigned to the Wisconsin Alumni Research Foundation (“WARF”) and licensed to Geron, covers human embryonic stem cells and is one of three WARF patents which were upheld in earlier reexamination proceedings. The immediate effect of the BPAI decisions is that WARF will have the opportunity to continue examination of the claims of the ‘913 patent at the examination level of the Patent Office.
